These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 36854094)

  • 1. Adjuvant Gemcitabine and Nab-Paclitaxel Misses the Target in Pancreas Adenocarcinoma: Or Did an Effective Therapy Fall to the Definition of Recurrence?
    Manji GA
    J Clin Oncol; 2023 Apr; 41(11):1972-1975. PubMed ID: 36854094
    [No Abstract]   [Full Text] [Related]  

  • 2. Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment.
    Petrillo A; Pappalardo A; Pompella L; Tirino G; Calabrese F; Laterza MM; Caterino M; Ventriglia A; Orditura M; Conzo G; Molino C; Ciardiello F; Biglietto M; De Vita F
    Med Oncol; 2019 Aug; 36(10):83. PubMed ID: 31444639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Nab-paclitaxel use in pancreatic cancer: practical aspects and consequences in a French oncology day-care unit].
    Hubault M; Faure R; Walter T; Forestier J; Lombard-Bohas C; Pivot C
    Bull Cancer; 2015 May; 102(5):403-4. PubMed ID: 25866372
    [No Abstract]   [Full Text] [Related]  

  • 4. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
    Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nab-Paclitaxel plus Gemcitabine for Patients with Recurrence after Resection for Adenocarcinoma of the Pancreas].
    Kawaida H; Hosomura N; Amemiya H; Higuchi Y; Tsukahara I; Nakayama T; Saito R; Shoda K; Nakata Y; Furuya S; Akaike H; Kawaguchi Y; Sudo M; Kono H; Ichikawa D
    Gan To Kagaku Ryoho; 2021 Jan; 48(1):107-109. PubMed ID: 33468736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
    Zong Y; Yuan J; Peng Z; Lu M; Wang X; Shen L; Zhou J
    J Cancer Res Clin Oncol; 2021 May; 147(5):1529-1536. PubMed ID: 33191450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
    Von Hoff DD; Ervin T; Arena FP; Chiorean EG; Infante J; Moore M; Seay T; Tjulandin SA; Ma WW; Saleh MN; Harris M; Reni M; Dowden S; Laheru D; Bahary N; Ramanathan RK; Tabernero J; Hidalgo M; Goldstein D; Van Cutsem E; Wei X; Iglesias J; Renschler MF
    N Engl J Med; 2013 Oct; 369(18):1691-703. PubMed ID: 24131140
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Korn RL; Von Hoff DD; Borad MJ; Renschler MF; McGovern D; Curtis Bay R; Ramanathan RK
    Cancer Imaging; 2017 Aug; 17(1):23. PubMed ID: 28774338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Congestive heart failure secondary to gemcitabine nab-paclitaxel in patients with pancreatic cancer.
    John P; Butler H; Saif MW
    Anticancer Res; 2014 Dec; 34(12):7267-70. PubMed ID: 25503159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results.
    Carrato A; Vieitez JM; Benavides M; Rodriguez-Garrote M; Castillo A; Ogalla GD; Bermejo LG; Ruiz de Mena I; Guillén-Ponce C; Aranda E;
    Eur J Cancer; 2020 Nov; 139():51-58. PubMed ID: 32977220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma.
    Bekaii-Saab T
    Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):5-7. PubMed ID: 30807560
    [No Abstract]   [Full Text] [Related]  

  • 13. Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
    Sahoo RK; Kumar L
    N Engl J Med; 2014 Jan; 370(5):478-9. PubMed ID: 24476440
    [No Abstract]   [Full Text] [Related]  

  • 14. Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
    Saltz LB; Bach PB
    N Engl J Med; 2014 Jan; 370(5):478. PubMed ID: 24476439
    [No Abstract]   [Full Text] [Related]  

  • 15. Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
    Von Hoff DD; Goldstein D; Renschler MF
    N Engl J Med; 2014 Jan; 370(5):479-80. PubMed ID: 24476438
    [No Abstract]   [Full Text] [Related]  

  • 16. Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer.
    Borazanci E; Von Hoff DD
    Expert Rev Gastroenterol Hepatol; 2014 Sep; 8(7):739-47. PubMed ID: 24882381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.
    Weiss GJ; Blaydorn L; Beck J; Bornemann-Kolatzki K; Urnovitz H; Schütz E; Khemka V
    Invest New Drugs; 2018 Feb; 36(1):96-102. PubMed ID: 29119276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma.
    Noel M; O'Reilly EM; Wolpin BM; Ryan DP; Bullock AJ; Britten CD; Linehan DC; Belt BA; Gamelin EC; Ganguly B; Yin D; Joh T; Jacobs IA; Taylor CT; Lowery MA
    Invest New Drugs; 2020 Jun; 38(3):800-811. PubMed ID: 31297636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant
    Peterson SL; Husnain M; Pollack T; Pimentel A; Loaiza-Bonilla A; Westendorf-Overley C; Ratermann K; Anthony L; Desimone P; Goel G; Kudrimoti M; Dineen S; Tzeng CD; Hosein PJ
    Anticancer Res; 2018 Jul; 38(7):4035-4039. PubMed ID: 29970528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer.
    Gharaibeh M; McBride A; Bootman JL; Patel H; Abraham I
    J Med Econ; 2017 Apr; 20(4):345-352. PubMed ID: 27919186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.